Quantcast

Global Pruritus Clinical Trial Pipeline Highlights, 2019 – Analysis on Clinical Trial Stages, Drug Mechanism Classes, Short-term Launch Highlights, and Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Pruritus Clinical Trial Pipeline Highlights, 2019”
report has
been added to ResearchAndMarkets.com’s offering.

This report provides most up-to-date information on key pipeline
products in the global Pruritus market. It covers emerging therapies for
Pruritus in active clinical development stages including early and late
stage clinical trials.

The pipeline data presented in this report helps executives for tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.

Clinical Trial Stages

The report provides Pruritus pipeline products by clinical trial stages
including both early and late stage development – phase 3 clinical
trials, phase 2 clinical trials, phase 1 clinical trials, preclinical
research, and discovery stage.

Drug Mechanism Classes

The report provides Pruritus pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.

Company

The report provides Pruritus pipeline products by the company.

Short-term Launch Highlights

Find out which Pruritus pipeline products will be launched in the US and
Ex-US till 2024.

Key Topics Covered

1. Pruritus Pipeline by Stages

2. Pruritus Phase 3 Clinical Trial Insights

3. Pruritus Phase 2 Clinical Trial Insights

4. Pruritus Phase 1 Clinical Trial Insights

5. Pruritus Preclinical Research Insights

6. Pruritus Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/37hqd4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials
, Dermatological
Drugs

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.